Cephalon Reinvention Puts Biologics Front And Center
Through several acquisitions and alliances completed over the last year, Cephalon has patched together a substantial pipeline of biologic drugs, an area of business the specialty pharma is ramping up as it looks to diversify its portfolio beyond wakefulness and pain
You may also be interested in...
Cephalon is making a significant bet on an Australian biotech's adult stem cell technology, taking it forward in multiple indications, including some fields where it isn't currently active, but which its executives say it can get up to speed on quickly. The deal is the specialty pharma company's fourth in biologics since it announced nearly two years ago that expanding into biologics would be a priority
The U.S. specialty pharma continues its multi-year effort to expand into biologics by licensing in the Australian biotech's adult stem cell technology for cardiovascular, oncology, and neurodegenerative indications.
Founder and CEO Frank Baldino is taking a temporary medical leave of absence, but the company says he will be back before the end of the year.